In vivo efficacy data will be presented for two lead therapeutic programs in development to treat rare genetic metabolic disorders

 CAMBRIDGE, Mass. – June 11, 2015 – Synlogic, Inc., a biotechnology company pioneering the development of therapeutic synthetic life, today announced that the company will be presenting scientific and corporate updates at several upcoming conferences, detailed below. For the first time, the Company will be releasing in vivo efficacy data highlighting the recent successes achieved with the Company’s two lead programs in development to treat the orphan genetic metabolic conditions Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).

“Synlogic’s upcoming presentation schedule exemplifies the robust translational efficiency of our platform engine. In the six months since initiating our scientific operations, the team has demonstrated in vivo proof of concept in our two lead programs focused on UCD and PKU; and advanced three subsequent programs, which will be entering into preclinical models shortly,” said Jose-Carlos (JC) Gutiérrez-Ramos, Ph.D., President and Chief Executive Officer at Synlogic. “The data generated in UCD and PKU demonstrates potent therapeutic activity, with the amount of toxic metabolites being eliminated to a level that will translate into differentiated clinical efficacy, providing an improved therapy for these congenital metabolic disorders. Our synthetic life platform technology radically transforms the development of medicines through its exquisite biosensory and bioremediation capabilities allowing for a new age of personalized, tunable therapeutics.”

Event:
SEED: Synthetic Biology Engineering, Evolution & Design Conference
http://synbioconference.org/2015

Title: Engineering E. coli Nissle to Degrade Toxic Compounds in Mouse Models of Metabolic Disease
Presenter:  Jonathan Kotula, Scientist
Date: Thursday, June 11
Location: Park Plaza Hotel, Boston, Mass.

Event:
BIO 2015
http://convention.bio.org/2015/

Title: Company Overview
Presenter: Alison Silva, Chief Operating Officer
Session: Platform for Therapeutics
Date: Wednesday, July 17
Time: 1:45 PM (Theater 4)
Location: Pennsylvania Convention Center, Philadelphia, Penn.

Event:
Gordon Research Conference: Synthetic Biology, Advancing Biosystems Design
https://www.grc.org/programs.aspx?id=15842

Title: Engineered E. coli Nissle, a Synthetic Commensal Bacteria that Sequesters Ammonia in Mouse Models of Urea Cycle Disorder
Presenter: Jonathan Kotula, Scientist
Location: Sunday River Resort, Newry, Maine

Event:
Gordon Research Conference: Synthetic Biology, Advancing Biosystems Design
https://www.grc.org/programs.aspx?id=15842

Title: A Genetically Engineered E. coli Nissle Strain that Reduces Serum Phenylalanine Levels in a Mouse Model of Phenylketonuria (PKU)
Presenter: Vincent Isabella, Scientist
Location: Sunday River Resort, Newry, Maine

Event:
4^th International RASopathies Symposium
https://rasopathiesnet.org/rasopathies/meetings/2015-symposium/

Presenter: Alison Silva, Chief Operating Officer
Session: Collaborations, Industry & Funding: Discuss mechanisms for collaborations translating into clinical trials
Date: Saturday, July 18
Time: 4:35 PM
Location: Seattle, Wash.

Event:
Gordon Research Conference: Microbial Adhesion and Signal Transduction
https://www.grc.org/programs.aspx?id=11671

Title: In vivo Characterization of Stress-responsive Promoters in the Normal and Inflamed Murine Gastrointestinal Tract
Presenter: Paul Miller, Ph.D., Chief Scientific Officer
Location: Salve Regina University, Newport, R.I.

About the Synlogic Drug Discovery Engine
The Synlogic drug discovery engine is based on an engineering methodology that uses standardized and well-characterized interchangeable parts, as well as cutting-edge, logical gene-circuit control features. These unique and proprietary elements allow the scientific team to rapidly design, build and test synthetic life that leverage the microorganisms (bacteria and viruses) that live in and interact with the human body and transform them into programmable symbiotic living therapeutics that exhibit exquisite genetic control in response to pathophysiological signals. In a very short time, Synlogic has applied this platform to develop two lead programs in rare diseases that are advancing towards clinical development. Synlogic’s programs for the treatment of urea cycle disorders and for the treatment of phenylketoniuria exemplify the power of synthetic biology to offer patients a safe and effective alternative to current therapies and the broad applicability of the company’s platform.

About Synlogic Inc.
Synlogic is a private biotechnology company based in Cambridge, Massachusetts focused on delivering the potential of next generation synthetic biology to patients. Synlogic leverages the most advanced technology platform available for the creation of therapeutic microbes with the goal to make significant advancements in the treatment of disease. Founded in 2014, Synlogic is backed by world-class life science investors, including Atlas Venture, New Enterprise Associates (NEA) and the Bill & Melinda Gates Foundation. For more information, please visit: http://synlogictx.com/.

CONTACT:

Synlogic, Inc.
Alison Silva
Chief Operating Officer
617-299-8404

Maureen L. Suda (Media)
Suda Communications LLC
585-387-9248